Published in J Thorac Oncol on January 01, 2015
Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | NCT03711422
Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series. Medicine (Baltimore) (2015) 0.85
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. Oncotarget (2016) 0.84
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. BioDrugs (2015) 0.82
Rapid Response to High-Dose, Pulsatile Erlotinib in Afatinib-Refractory Leptomeningeal Carcinomatosis from Adenocarcinoma of the Lung: A Case Report. Case Rep Oncol (2016) 0.81
Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports. Medicine (Baltimore) (2017) 0.78
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options. ESMO Open (2016) 0.77
Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer: Can High-Affinity TKI Substitute for High-Dose TKI? J Thorac Oncol (2015) 0.77
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Front Oncol (2017) 0.77
A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer. Curr Treat Options Oncol (2017) 0.75
New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong? Onco Targets Ther (2016) 0.75
Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy. Transl Lung Cancer Res (2016) 0.75
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol (2017) 0.75
Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report. Open Med (Wars) (2016) 0.75
Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions. Int J Mol Sci (2016) 0.75
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. Springerplus (2016) 0.75
Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. Front Med (Lausanne) (2017) 0.75
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clin Cancer Res (2015) 0.75
Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice. Acta Pharmacol Sin (2016) 0.75
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Transl Lung Cancer Res (2016) 0.75
Erlotinib plus concurrent whole-brain radiation therapy for non-small cell lung cancers patients with multiple brain metastases. Transl Lung Cancer Res (2016) 0.75
MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor. Oncotarget (2017) 0.75
Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature. Front Oncol (2017) 0.75
Efficacy and Safety Results of the Afatinib Expanded Access Program. Oncol Ther (2017) 0.75
Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. Front Oncol (2017) 0.75
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 11.68
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 5.82
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res (2006) 4.72
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov (2014) 4.55
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol (2006) 2.82
Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol (2006) 2.76
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res (2005) 2.72
Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther (2012) 2.63
Multidisciplinary management of brain metastases. Oncologist (2007) 2.15
Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer (1981) 2.05
Current management of brain metastases, with a focus on systemic options. J Clin Oncol (2005) 1.95
Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol (2013) 1.93
Circumventing resistance to kinase-inhibitor therapy. N Engl J Med (2006) 1.75
EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol (2010) 1.73
Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol (2013) 1.50
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer (2009) 1.47
Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res (2005) 1.47
Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference? J Clin Oncol (2013) 1.40
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol (2010) 1.34
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist (2007) 1.33
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol (2009) 1.30
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol (2011) 1.24
Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer (2011) 1.22
USE OF GLUCOCORTICOIDS IN THE PALLIATIVE TREATMENT OF METASTATIC BRAIN TUMORS. Cancer (1965) 1.07
Neurotoxicity of radiation therapy. Neurol Clin (2010) 1.06
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J Thorac Oncol (2011) 1.03
Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet (2013) 1.03
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res (2006) 1.03
CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer (2013) 1.00
Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Exp Med (2008) 0.95
Targeting EGFR in non-small-cell lung cancer. N Engl J Med (2005) 0.90
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib. Oncologist (2014) 0.88
Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients. Onco Targets Ther (2013) 0.87
Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases. Lung Cancer (2013) 0.87
Treatment of brain metastases. J Support Oncol (2004) 0.85
Defining clinically relevant molecular subsets of lung cancer. Cancer Chemother Pharmacol (2006) 0.84
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol (2013) 4.55
The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol (2011) 2.79
A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci (2003) 2.34
TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med (2012) 1.94
PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am J Physiol Lung Cell Mol Physiol (2003) 1.74
Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension (2007) 1.68
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol (2012) 1.50
Aging reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female spontaneously hypertensive rats. Hypertension (2006) 1.49
High-accuracy computation of reaction barriers in enzymes. Angew Chem Int Ed Engl (2006) 1.43
Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol (2005) 1.42
The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer (2007) 1.36
Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. AIDS (2012) 1.28
Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer (2007) 1.28
Novel non-viral method for transfection of primary leukemia cells and cell lines. Genet Vaccines Ther (2004) 1.22
Interaction energy contributions of H-bonded and stacked structures of the AT and GC DNA base pairs from the combined density functional theory and intermolecular perturbation theory approach. J Am Chem Soc (2006) 1.13
Hypobaric hypoxia causes body weight reduction in obese subjects. Obesity (Silver Spring) (2010) 1.12
Gene expression profiling of malignant mesothelioma. Clin Cancer Res (2003) 1.10
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother (2007) 1.08
Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother (2004) 1.06
Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc Res (2007) 1.06
Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. J Immunother (2009) 1.05
A conclusive mechanism of the photoinduced reaction cascade in blue light using flavin photoreceptors. J Am Chem Soc (2008) 1.04
Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin Dev Immunol (2007) 1.02
Minimal size MIDGE vectors improve transgene expression in vivo. In Vivo (2007) 1.01
The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer. Tumour Biol (2008) 1.00
Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring. J Immunother (2007) 1.00
Platelet-endothelial cell adhesion molecule-1-directed immunotargeting to cardiopulmonary vasculature. J Pharmacol Exp Ther (2002) 1.00
Streptavidin-biotin crosslinking of therapeutic enzymes with carrier antibodies: nanoconjugates for protection against endothelial oxidative stress. Methods Mol Biol (2004) 0.98
Nek9 phosphorylation of NEDD1/GCP-WD contributes to Plk1 control of γ-tubulin recruitment to the mitotic centrosome. Curr Biol (2012) 0.97
Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue. Anticancer Res (2009) 0.96
Non-invasive ventilation in immunosuppressed patients with pneumonia and extrapulmonary sepsis. Respir Med (2012) 0.94
Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother (2009) 0.94
Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR. Hypertension (2003) 0.94
Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. J Thorac Oncol (2013) 0.94
A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab (2005) 0.94
Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer. J Thorac Oncol (2014) 0.94
Characterization of the interstitial lung and peripheral blood T cell receptor repertoire in cigarette smokers. Am J Respir Cell Mol Biol (2004) 0.93
PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother (2006) 0.92
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs (2014) 0.92
Influence of air pressure, humidity, solar radiation, temperature, and wind speed on ambulatory visits due to chronic obstructive pulmonary disease in Bavaria, Germany. Int J Biometeorol (2011) 0.91
Stacking energies for average B-DNA structures from the combined density functional theory and symmetry-adapted perturbation theory approach. J Am Chem Soc (2008) 0.91
Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany. Oncol Res Treat (2014) 0.90
Response to chemotherapy, reexposure to crizotinib and treatment with a novel ALK inhibitor in a patient with acquired crizotinib resistance. Respiration (2014) 0.90
PECAM-directed immunotargeting of catalase: specific, rapid and transient protection against hydrogen peroxide. Free Radic Biol Med (2003) 0.90
Estrogen and estrogen receptors in cardiovascular oxidative stress. Pflugers Arch (2013) 0.89
Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy? World J Gastroenterol (2007) 0.88
5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. J Immunother (2012) 0.88
c-kit expression in adenocarcinomas of the lung. Tumour Biol (2005) 0.87
Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res (2003) 0.87
Targeted endothelial delivery of nanosized catalase immunoconjugates protects lung grafts donated after cardiac death. Transplantation (2011) 0.86
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol (2008) 0.86
Genetic and pharmacologic strategies to determine the function of estrogen receptor alpha and estrogen receptor beta in cardiovascular system. Gend Med (2008) 0.86
Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells. Cancer Res (2006) 0.86
An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res (2002) 0.86
Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother (2008) 0.85
Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy. Mol Ther (2002) 0.85
Thoracoscopic resection of a giant midesophageal diverticulum. Ann Thorac Surg (2012) 0.85
Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. J Urol (2004) 0.85
Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunol Immunother (2006) 0.85
Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer. J Thorac Oncol (2011) 0.84
Real-time high-resolution compound imaging allows percutaneous initiation and surveillance in an orthotopic murine pancreatic cancer model. Pancreas (2008) 0.84
Interferon-alpha restitutes the chemosensitivity in pancreatic cancer. Anticancer Res (2008) 0.84
Theoretical study on the repair mechanism of the (6-4) photolesion by the (6-4) photolyase. J Am Chem Soc (2010) 0.84
On the physisorption of water on graphene: a CCSD(T) study. Phys Chem Chem Phys (2011) 0.84
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. Anticancer Drugs (2010) 0.84
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer (2014) 0.83
The European initiative for quality management in lung cancer care. Eur Respir J (2014) 0.83
Image-guided hypofractionated small volume radiotherapy of non-small cell lung cancer - feasibility and clinical outcome. Onkologie (2012) 0.83
A key regulatory role of the transcription factor NFATc2 in bronchial adenocarcinoma via CD8+ T lymphocytes. Cancer Res (2009) 0.83
Endoplasmic reticulum Ca2+-homeostasis is altered in Small and non-small Cell Lung Cancer cell lines. J Exp Clin Cancer Res (2009) 0.83
Gene therapy for lung neoplasms. Clin Chest Med (2002) 0.82
Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. Hypertension (2006) 0.82
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol (2008) 0.82
Estrogen receptor alpha interacts with 17beta-hydroxysteroid dehydrogenase type 10 in mitochondria. Biochem Biophys Res Commun (2009) 0.81
Tacrolimus preconditioning of rat liver allografts impacts glutathione homeostasis and early reperfusion injury. J Surg Res (2011) 0.81
Enhancement of anti-tumor activity in vitro and in vivo by CD150 and SAP. Mol Immunol (2007) 0.81
Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer. PLoS One (2012) 0.81
Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. World J Gastroenterol (2005) 0.81
Release of iC3b from apoptotic tumor cells induces tolerance by binding to immature dendritic cells in vitro and in vivo. Cancer Immunol Immunother (2005) 0.81
Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer. Oncol Rep (2006) 0.81
Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother (2008) 0.81
SAP and SLAM expression in anti-CD3 activated lymphocytes correlates with cytotoxic activity. Immunol Cell Biol (2005) 0.81
DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes. Clin Cancer Res (2013) 0.80
Examination of external validity in randomized controlled trials for adjuvant treatment of pancreatic adenocarcinoma. Pancreas (2009) 0.80
Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo. Cancer (2006) 0.80
Assessment of patient satisfaction with postoperative pain management after ambulatory gynaecologic laparoscopy. J Obstet Gynaecol Can (2007) 0.80
TA-MUC1 epitope in non-small cell lung cancer. Lung Cancer (2008) 0.80
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer (2014) 0.79
Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes. J Immunol Methods (2005) 0.79
A QM/MM study on the fast photocycle of blue light using flavin photoreceptors in their light-adapted/active form. Phys Chem Chem Phys (2010) 0.79
The estrogen receptor-α is required and sufficient to maintain physiological glucose uptake in the mouse heart. Hypertension (2012) 0.79
Approaching the theoretical limit in periodic local MP2 calculations with atomic-orbital basis sets: the case of LiH. J Chem Phys (2011) 0.79
Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology (2014) 0.79
Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease. Toxicol Pathol (2009) 0.79
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104. Acta Oncol (2015) 0.79
An efficient local coupled cluster method for accurate thermochemistry of large systems. J Chem Phys (2011) 0.78
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. Oncologist (2015) 0.78